Literature DB >> 34458739

Discovery, synthesis and biological characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators.

Swagat Sharma1, Lauren Lesiak1, Christopher D Aretz1, Yu Du2, Sushil Kumar1, Nagsen Gautam1, Yazen Alnouti1, Nikilesh V Dhuria3, Yashpal S Chhonker3, C David Weaver2, Corey R Hopkins1.   

Abstract

The present study describes the discovery and characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as G protein-gated inwardly-rectifying potassium (GIRK) channel activators. From our previous lead optimization efforts, we have identified a new ether-based scaffold and paired this with a novel sulfone-based head group to identify a potent and selective GIRK1/2 activator. In addition, we evaluated the compounds in tier 1 DMPK assays and have identified compounds that display nanomolar potency as GIRK1/2 activators with improved metabolic stability over the prototypical urea-based compounds. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34458739      PMCID: PMC8372201          DOI: 10.1039/d1md00129a

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  34 in total

1.  A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors.

Authors:  Colleen M Niswender; Kari A Johnson; Qingwei Luo; Jennifer E Ayala; Caroline Kim; P Jeffrey Conn; C David Weaver
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

Review 2.  G Protein-Gated Potassium Channels: A Link to Drug Addiction.

Authors:  Robert A Rifkin; Stephen J Moss; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2017-02-07       Impact factor: 14.819

3.  Heteromultimerization of G-protein-gated inwardly rectifying K+ channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain.

Authors:  Y J Liao; Y N Jan; L Y Jan
Journal:  J Neurosci       Date:  1996-11-15       Impact factor: 6.167

4.  Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators.

Authors:  Joshua M Wieting; Anish K Vadukoot; Swagat Sharma; Kristopher K Abney; Thomas M Bridges; J Scott Daniels; Ryan D Morrison; Kevin Wickman; C David Weaver; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2017-07-19       Impact factor: 4.418

5.  The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins.

Authors:  G Krapivinsky; E A Gordon; K Wickman; B Velimirović; L Krapivinsky; D E Clapham
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

6.  Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models.

Authors:  Kristopher K Abney; Michael Bubser; Yu Du; Krystian A Kozek; Thomas M Bridges; Craig W Linsdley; J Scott Daniels; Ryan D Morrison; Kevin Wickman; Corey R Hopkins; Carrie K Jones; C David Weaver
Journal:  ACS Chem Neurosci       Date:  2018-12-11       Impact factor: 4.418

7.  Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297.

Authors:  Nicole Wydeven; Ezequiel Marron Fernandez de Velasco; Yu Du; Michael A Benneyworth; Matthew C Hearing; Rachel A Fischer; Mark John Thomas; C David Weaver; Kevin Wickman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

Review 8.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

Review 9.  Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system.

Authors:  Danko Jeremic; Irene Sanchez-Rodriguez; Lydia Jimenez-Diaz; Juan D Navarro-Lopez
Journal:  Pharmacol Ther       Date:  2021-01-18       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.